FDA Grants Breakthrough Device Status to PathAI’s AI Dermatopathology Tool

PathAI has received breakthrough device designation from the U.S. Food and Drug Administration for PathAssist Derm, an artificial intelligence-powered dermatopathology workflow solution designed to assist pathologists in evaluating skin lesion samples.

PathAssist Derm analyses digital pathology whole slide images and supports specialists during the diagnostic review process. The system uses AI to prioritise cases and streamline workflows, helping pathologists manage growing diagnostic workloads more effectively.

The milestone follows several regulatory achievements for the company. PathAI recently secured 510(k) clearance from the FDA for AISight Dx, a digital pathology image management system approved with an authorised Predetermined Change Control Plan. The company also obtained qualification from both the European Medicines Agency and the FDA for AIM-MASH AI Assist, an AI-based pathology tool used in drug development.

Demand for advanced dermatopathology solutions is increasing as skin cancer cases rise in the US. Diagnostic variability among pathologists remains a challenge, particularly for melanocytic lesions.

PathAssist Derm applies AI-driven analysis to support case assessment and workflow prioritisation, helping improve diagnostic consistency and enabling pathologists to manage expanding caseloads more efficiently.

05-03-2026